BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ter Veer E, van Kleef JJ, Schokker S, van der Woude SO, Laarman M, Haj Mohammad N, Sprangers MAG, van Oijen MGH, van Laarhoven HWM. Prognostic and predictive factors for overall survival in metastatic oesophagogastric cancer: A systematic review and meta-analysis. Eur J Cancer 2018;103:214-26. [PMID: 30268922 DOI: 10.1016/j.ejca.2018.07.132] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 4.4] [Reference Citation Analysis]
Number Citing Articles
1 Wang L, Zhu L, Yan J, Qin W, Wang C, Xi W, Xu Z, Chen Y, Jiang J, Huang S, Yan C, Zhang H, Pan Z, Zhang J. CT-Based Radiomic Score: A Risk Stratifier in Far-Advanced Gastric Cancer Patients. Acad Radiol 2023:S1076-6332(22)00688-2. [PMID: 36610930 DOI: 10.1016/j.acra.2022.12.034] [Reference Citation Analysis]
2 Kroese TE, Takahashi Y, Lordick F, van Rossum PSN, Ruurda JP, Lagarde SM, van Hillegersberg R, Verhoeven RHA, van Laarhoven HWM. Liver oligometastatic disease in synchronous metastatic gastric cancer patients: a nationwide population-based cohort study. Eur J Cancer 2023;179:65-75. [PMID: 36509000 DOI: 10.1016/j.ejca.2022.11.011] [Reference Citation Analysis]
3 Fang T, Gong Y, Wang Y. Prognostic values of myosteatosis for overall survival in patients with gastric cancers: A meta-analysis with trial sequential analysis. Nutrition 2023;105:111866. [PMID: 36368263 DOI: 10.1016/j.nut.2022.111866] [Reference Citation Analysis]
4 Kroese TE, Jorritsma NK, van Laarhoven HW, Verhoeven RH, Mook S, Haj Mohammad N, Ruurda JP, van Rossum PS, van Hillegersberg R. Stereotactic radiotherapy or metastasectomy for oligometastatic esophagogastric cancer: a nationwide population-based cohort study. Clinical and Translational Radiation Oncology 2022. [DOI: 10.1016/j.ctro.2022.08.012] [Reference Citation Analysis]
5 Kroese TE, van Rossum PSN, van der Horst S, Mook S, Haj Mohammad N, Ruurda JP, van Hillegersberg R. Long-term survival after sequential local treatments for oligometastatic esophageal squamous cell carcinoma: A case report. Int J Surg Case Rep 2022;97:107423. [PMID: 35870217 DOI: 10.1016/j.ijscr.2022.107423] [Reference Citation Analysis]
6 Van Cutsem E, Kato K, Ajani J, Shen L, Xia T, Ding N, Zhan L, Barnes G, Kim SB. Tislelizumab versus chemotherapy as second-line treatment of advanced or metastatic esophageal squamous cell carcinoma (RATIONALE 302): impact on health-related quality of life. ESMO Open 2022;7:100517. [PMID: 35785595 DOI: 10.1016/j.esmoop.2022.100517] [Reference Citation Analysis]
7 Kroese TE, Christ SM, van Rossum PSN, Burger MDL, Buijs GS, Mühlematter U, Andratschke N, Ruurda JP, Hüllner M, Gutschow CA, van Hillegersberg R, Guckenberger M. Incidence and survival of patients with oligometastatic esophagogastric cancer: a multicenter cohort study. Radiother Oncol 2022:S0167-8140(22)04173-1. [PMID: 35753555 DOI: 10.1016/j.radonc.2022.06.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
8 Pijnappel EN, Suurmeijer JA, Koerkamp BG, Kos M, Siveke JT, Salvia R, Ghaneh P, van Eijck CHJ, van Etten-Jamaludin FS, Abrams R, Brasiuniene B, Büchler MW, Casadei R, van Laethem JL, Berlin J, Boku N, Conroy T, Golcher H, Sinn M, Neoptolemos JP, van Tienhoven G, Besselink MG, Wilmink JW, van Laarhoven HWM. Consensus Statement on Mandatory Measurements for Pancreatic Cancer Trials for Patients With Resectable or Borderline Resectable Disease (COMM-PACT-RB): A Systematic Review and Delphi Consensus Statement. JAMA Oncol 2022. [PMID: 35446336 DOI: 10.1001/jamaoncol.2022.0168] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
9 Kroese TE, van Laarhoven HWM, Nilsson M, Lordick F, Guckenberger M, Ruurda JP, D'Ugo D, Haustermans K, van Cutsem E, van Hillegersberg R, van Rossum PSN. Definition of oligometastatic esophagogastric cancer and impact of local oligometastasis-directed treatment: A systematic review and meta-analysis. Eur J Cancer 2022;166:254-69. [PMID: 35339868 DOI: 10.1016/j.ejca.2022.02.018] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 9.0] [Reference Citation Analysis]
10 Koo DH, Ryu MH, Lee MY, Moon MS, Kang YK. New prognostic model for patients with advanced gastric cancer: Fluoropyrimidine/platinum doublet for first-line chemotherapy. World J Gastroenterol 2021; 27(48): 8357-8369 [DOI: 10.3748/wjg.v27.i48.8357] [Reference Citation Analysis]
11 van de Water LF, van den Boorn HG, Hoxha F, Henselmans I, Calff MM, Sprangers MAG, Abu-Hanna A, Smets EMA, van Laarhoven HWM. Informing Patients With Esophagogastric Cancer About Treatment Outcomes by Using a Web-Based Tool and Training: Development and Evaluation Study. J Med Internet Res 2021;23:e27824. [PMID: 34448703 DOI: 10.2196/27824] [Reference Citation Analysis]
12 van Velzen MJM, Pape M, Dijksterhuis WPM, Slingerland M, van Voorthuizen T, Beerepoot LV, Creemers GJ, Derks S, Mohammad NH, Verhoeven RHA, van Laarhoven HWM. The association between effectiveness of first-line treatment and second-line treatment in gastro-oesophageal cancer. Eur J Cancer 2021;156:60-9. [PMID: 34425405 DOI: 10.1016/j.ejca.2021.07.026] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
13 van Kleef JJ, Dijksterhuis WPM, van den Boorn HG, Prins M, Verhoeven RHA, Gisbertz SS, Slingerland M, Mohammad NH, Creemers GJ, Neelis KJ, Heisterkamp J, Rosman C, Ruurda JP, Kouwenhoven EA, van de Poll-Franse LV, van Oijen MGH, Sprangers MAG, van Laarhoven HWM; Dutch Upper GI Cancer Group (DUCG). Prognostic value of patient-reported quality of life for survival in oesophagogastric cancer: analysis from the population-based POCOP study. Gastric Cancer 2021. [PMID: 34251543 DOI: 10.1007/s10120-021-01209-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
14 Kim J, Hong JY, Kim ST, Park SH, Jekal SY, Choi JS, Chang DK, Kang WK, Seo SW, Lee J. Clinical scoring system for the prediction of survival of patients with advanced gastric cancer. ESMO Open 2020;5:e000670. [PMID: 32188716 DOI: 10.1136/esmoopen-2020-000670] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
15 Kos M, Pijnappel EN, Buffart LM, Balvers BR, Kampshoff CS, Wilmink JW, van Laarhoven HWM, van Oijen MGH. The association between wearable activity monitor metrics and performance status in oncology: a systematic review. Support Care Cancer 2021. [PMID: 34117567 DOI: 10.1007/s00520-021-06234-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
16 Rimini M, Pecchi A, Prampolini F, Bussei C, Salati M, Forni D, Martelli F, Valoriani F, Canino F, Bocconi A, Gelsomino F, Reverberi L, Benatti S, Piacentini F, Menozzi R, Dominici M, Luppi G, Spallanzani A. The Prognostic Role of Early Skeletal Muscle Mass Depletion in Multimodality Management of Patients with Advanced Gastric Cancer Treated with First Line Chemotherapy: A Pilot Experience from Modena Cancer Center. J Clin Med 2021;10:1705. [PMID: 33921004 DOI: 10.3390/jcm10081705] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
17 Mohammed AA, Al-Zahrani O, Elsayed FM, Elshentenawy A. Prediction of Survival Outcome Using Chuang's Prognostic Scale in Metastatic Breast Cancer. Indian J Palliat Care 2021;27:43-6. [PMID: 34035616 DOI: 10.4103/IJPC.IJPC_97_20] [Reference Citation Analysis]
18 van de Water LF, van den Boorn HG, Hoxha F, Henselmans I, Calff MM, Sprangers MAG, Abu-hanna A, Smets EMA, van Laarhoven HWM. Informing Patients With Esophagogastric Cancer About Treatment Outcomes by Using a Web-Based Tool and Training: Development and Evaluation Study (Preprint).. [DOI: 10.2196/preprints.27824] [Reference Citation Analysis]
19 Pijnappel EN, Suurmeijer JA, Groot Koerkamp B, Siveke JT, Salvia R, Ghaneh P, Besselink MG, Wilmink JW, van Laarhoven HWM. Mandatory Reporting Measurements in Trials for Potentially Resectable Pancreatic Cancer. Textbook of Pancreatic Cancer 2021. [DOI: 10.1007/978-3-030-53786-9_8] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
20 van Velzen MJM, Derks S, van Grieken NCT, Haj Mohammad N, van Laarhoven HWM. MSI as a predictive factor for treatment outcome of gastroesophageal adenocarcinoma. Cancer Treat Rev 2020;86:102024. [PMID: 32388292 DOI: 10.1016/j.ctrv.2020.102024] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 13.7] [Reference Citation Analysis]
21 van Kleef JJ, van den Boorn HG, Verhoeven RHA, Vanschoenbeek K, Abu-Hanna A, Zwinderman AH, Sprangers MAG, van Oijen MGH, De Schutter H, van Laarhoven HWM. External Validation of the Dutch SOURCE Survival Prediction Model in Belgian Metastatic Oesophageal and Gastric Cancer Patients. Cancers (Basel) 2020;12:E834. [PMID: 32244310 DOI: 10.3390/cancers12040834] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
22 Ter Veer E, van Oijen MGH, van Laarhoven HWM. The Use of (Network) Meta-Analysis in Clinical Oncology. Front Oncol 2019;9:822. [PMID: 31508373 DOI: 10.3389/fonc.2019.00822] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 6.0] [Reference Citation Analysis]
23 Dijksterhuis WPM, Verhoeven RHA, Slingerland M, Haj Mohammad N, de Vos-Geelen J, Beerepoot LV, van Voorthuizen T, Creemers GJ, van Oijen MGH, van Laarhoven HWM. Heterogeneity of first-line palliative systemic treatment in synchronous metastatic esophagogastric cancer patients: A real-world evidence study. Int J Cancer. 2020;146:1889-1901. [PMID: 31340065 DOI: 10.1002/ijc.32580] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 5.3] [Reference Citation Analysis]
24 Faron M, Pignon JP, Paoletti X. Meta-analysis of prognostic and predictive factors: Towards individual participant data? Eur J Cancer 2018;104:224-6. [PMID: 30454708 DOI: 10.1016/j.ejca.2018.09.023] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]